The shot targets the original variant, along with Omicron
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a bivalent version of Moderna’s COVID-19 vaccine that targets both the original and Omicron strains of the virus. The decision follows an endorsement of the booster from the UK’s Commission on Human Medicines (CHM), the government’s independent scientific advisory board.
The decision was based on a clinical trial which demonstrated that the booster triggers a strong immune response against the original COVID strain and BA.1, the first Omicron strain. It also demonstrated a good immune response against Omicron sub-variants BA.4 and BA.5. Side-effects and overall safety profile were found to be the same as those in the original vaccine.
“The first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives,” notes June Raine, chief executive, MHRA. “What this bivalent vaccine gives us is a sharpened tool in our armory to help protect us against this disease as the virus continues to evolve.”
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.